文献速递胸部肿瘤放疗

II期非小细胞肺癌根治性治疗的人群分析:放疗在医学不可手术患者中的作用

Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients.
PubMed 文献 · Radiat Oncol · 2020-01-30

该回顾性研究分析了2005至2012年转诊至BC癌症机构的535例II期NSCLC患者,其中46%接受根治性手术、25%接受根治性放疗、30%未接受根治性治疗。手术组中位OS为61.4个月,根治性放疗组为26.5个月,非根治性治疗组为13.1个月;配对分析中手术组中位OS仍优于放疗组(101.6个月 vs 28.1个月)。多因素分析显示ECOG PS、体重减轻和治疗队列影响生存;根治性放疗患者中同步化疗和RT剂量≥60Gy与更好的结局相关。

要点

  • II期NSCLC中仅46%接受根治性手术,25%接受根治性放疗,30%未接受根治性治疗。
  • 手术组中位OS为61.4个月,根治性放疗组为26.5个月,非根治性治疗组为13.1个月。
  • 根治性放疗患者中同步化疗和RT剂量≥60Gy与改善的结局相关。

核心结论

  • II期NSCLC中许多患者无法接受标准手术切除,放疗对不可手术患者提供了较差但仍属根治性的选择。

研究设计与样本

  • 回顾性分析2005至2012年转诊至BC癌症机构的II期NSCLC患者,共535例,比较根治性手术与根治性放疗的生存。

主要发现

  • 535例患者中245例(46%)接受根治性手术,132例(25%)接受根治性放疗,158例(30%)未接受根治性治疗。
  • 手术组、根治性放疗组和非根治性治疗组的中位OS分别为61.4个月、26.5个月和13.1个月,组间差异显著。
  • 配对分析中手术组中位OS为101.6个月,根治性放疗组为28.1个月。
  • 多因素分析显示ECOG PS、体重减轻和治疗队列影响生存。
  • 根治性放疗患者中同步化疗和RT剂量≥60Gy与改善的结局相关。

关键数值与推荐

  • 根治性放疗患者中,同步化疗和RT剂量≥60Gy与改善的结局相关。

临床怎么用

  • 对于医学不可手术的II期NSCLC患者,根治性放疗是可考虑的根治性替代方案。
  • 根治性放疗时关注同步化疗和RT剂量≥60Gy可能改善结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Curative intent therapy of stage II NSCLC may include surgical resection or definitive radiotherapy. Primary management with surgery or radiotherapy may be influenced by patient and disease characteristics. We sought to perform a comparison of patients receiving surgery or radical radiation therapy as their curative treatment, and explore the impact of known prognostic factors on outcome. MATERIALS AND METHODS: A retrospective review was completed of all patients with stage II NSCLC referred to the BC Cancer Agency from 2005 to 2012. Cases were filtered to identify those receiving curative intent therapy including surgery or radiotherapy. Information was collected on known prognostic and predictive factors. The primary outcome measure was overall survival. We compared survival among patients receiving curative intent radiotherapy versus surgical intervention. RESULTS: A total of 535 patients were referred. Of these, 245 (46%) received curative intent surgery, 132 (25%) curative intent radiotherapy, and 158 (30%) did not receive curative therapy. There were significant differences between cohorts with respect to median age, histology, ECOG PS, smoking status, and weight loss. Median OS was significantly different between cohorts: 61.4 m surgery, 26.5 m curative RT, and 13.1 m non-curative therapy. In a case-matched analysis, median OS remained superior for surgery at 101.6 m vs 28.1 m for curative RT. In a multivariate analysis, ECOG PS, weight loss, and treatment cohort all influenced survival. Among patients receiving curative intent radiotherapy, the use of concurrent chemotherapy and RT dose > = 60Gy were associated with improved outcomes. CONCLUSIONS: Among patients with stage II NSCLC, many are unable to undergo standard of care surgical resection. Radiotherapy provides an inferior yet still curative option in the management of inoperable patients. Further work is needed to optimize outcomes in this population.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Moore S, Leung B, Wu J, et al. Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients. Radiat Oncol. 2020. PMID: 32000829. doi:10.1186/s13014-020-1466-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。